In prostate cancer cells, SIRT7 cooperates with SIRT1 to suppress E-cadherin regulatory genes to promote EMT, and high SIRT7 levels are associated with metastatic disease and poor prognosis (Malik et al., 2015). Here, SIRT7 is linked to metastatic neoplasm.